Safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing progression to diabetes in a Chinese population with impaired glucose regulation: a multicentre, open-label, randomised controlled trial

医学 糖耐量受损 空腹血糖受损 二甲双胍 糖尿病 2型糖尿病 随机对照试验 人口 内科学 物理疗法 内分泌学 环境卫生
作者
Lihui Zhang,Yunliang Zhang,Sheng'ai Shen,Xueying Wang,Luling Dong,Qiuyun Li,Weidong Ren,Yufeng Li,Jianling Bai,Qiuhong Gong,Hongyu Kuang,Lin Qi,Qiang Lü,Wenli Cheng,Yanjie Liu,Shuang Yan,Dong‐Hong Wu,Hui Fang,Fang Hou,Yingju Wang
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:11 (8): 567-577 被引量:99
标识
DOI:10.1016/s2213-8587(23)00132-8
摘要

Summary

Background

Impaired glucose regulation (defined as either impaired glucose tolerance or impaired fasting glucose) is an important risk factor for the development of diabetes. We aimed to evaluate the safety and effectiveness of metformin plus lifestyle intervention compared with lifestyle intervention alone in preventing diabetes in Chinese participants with impaired glucose regulation.

Methods

We did a multicentre, open-label, randomised controlled trial at 43 endocrinology departments in general hospitals across China. Eligible participants were individuals with impaired glucose regulation (ie, impaired glucose tolerance or impaired fasting glucose, or both), men or women aged 18–70 years with a BMI of 21–32 kg/m2. Eligible participants were randomly assigned (1:1) via a computer-generated randomisation to receive either standard lifestyle intervention alone or metformin (850 mg orally once per day for the first 2 weeks and titrated to 1700 mg orally per day [850 mg twice per day]) plus lifestyle intervention. Block randomisation was used with a block size of four, stratified by glucose status (impaired fasting glucose or impaired glucose tolerance), hypertension, and use of any anti-hypertensive medication. Lifestyle intervention advice was given by investigators at all participating sites. The primary endpoint was the incidence of newly diagnosed diabetes at the end of the 2-year follow-up. Analysis was done using the full analysis set and per-protocol set. This study is registered with ClinicalTrials.gov, number NCT03441750, and is completed.

Findings

Between April, 2017, and June, 2019, 3881 individuals were assessed for eligibility, of which 1678 (43·2%) participants were randomly assigned to either the metformin plus lifestyle intervention group (n=831) or the lifestyle intervention alone group (n=847) and received the allocated intervention at least once. During a median follow-up of 2·03 years, the incidence rate of diabetes was 17·27 (95% CI 15·19–19·56) per 100 person-years in the metformin plus lifestyle intervention group and 19·83 (17·67–22·18) per 100 person-years in the lifestyle intervention alone group. The metformin plus lifestyle intervention group showed a 17% lower risk of developing diabetes than the lifestyle intervention alone group (HR 0·83 [95% CI 0·70–0·99]; log-rank p=0·043). A higher proportion of participants in the metformin plus lifestyle intervention group reported adverse events than in the lifestyle intervention alone group, primarily due to more gastrointestinal adverse events. The percentage of participants reporting a serious adverse event was similar in both groups.

Interpretation

Metformin plus lifestyle intervention further reduced the risk of developing diabetes than lifestyle intervention alone in Chinese people with impaired glucose regulation, showing additional benefits of combined intervention in preventing progression to diabetes without new safety concerns.

Funding

Merck Serono China, an affiliate of Merck KGaA, Darmstadt, Germany.

Translation

For the Chinese translation of the abstract see Supplementary Materials section.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
歪猴完成签到,获得积分10
刚刚
刚刚
孟志宇发布了新的文献求助10
刚刚
快乐十一给快乐十一的求助进行了留言
1秒前
1秒前
守夜人完成签到 ,获得积分10
1秒前
吕吕完成签到,获得积分10
1秒前
wang完成签到,获得积分10
2秒前
Yaqi发布了新的文献求助10
2秒前
Renea完成签到,获得积分10
2秒前
3秒前
3秒前
小郭发布了新的文献求助10
3秒前
3秒前
3秒前
Orange的应助被JH_采纳,获得10
4秒前
4秒前
4秒前
李健的小迷弟的应助被adai007采纳,获得10
4秒前
nepdiana的应助被勤劳的薯片采纳,获得30
4秒前
333完成签到,获得积分20
5秒前
Taro完成签到,获得积分10
5秒前
碧蓝山水完成签到,获得积分10
5秒前
nanana完成签到,获得积分10
5秒前
5秒前
6秒前
LZZZZZQ发布了新的文献求助10
6秒前
6秒前
小刘完成签到,获得积分10
6秒前
6秒前
ZS发布了新的文献求助10
7秒前
完美萤完成签到,获得积分10
8秒前
liuhll发布了新的文献求助10
8秒前
NexusExplorer的应助被好家伙采纳,获得10
8秒前
8秒前
mengxiang完成签到,获得积分20
8秒前
Ada完成签到 ,获得积分10
8秒前
zgw完成签到,获得积分10
8秒前
风禾尽起发布了新的文献求助10
8秒前
nauj完成签到 ,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180488
求助须知:如何正确求助?哪些是违规求助? 9570485
关于积分的说明 21812623
捐赠科研通 7776592
什么是DOI,文献DOI怎么找? 3433286
关于科研通互助平台的介绍 2557522
邀请新用户注册赠送积分活动 2479162